A randomized trial of enhanced HIV risk-reduction and vaccine trial education interventions among HIV-negative, high-risk women who use noninjection drugs: The UNITY study

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 3, 2010, Pages 378-387

  Koblin, Beryl A ^a   Bonner, Sebastian ^b   Hoover, Donald R ^c   Xu, Guozhen ^a   Lucy, Debbie ^a   Fortin, Princess ^b   Putnam, Sara ^b   Latka, Mary H ^b  

^a NEW YORK BLOOD CENTER   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Behavioral intervention; HIV; Substance use; Vaccines,women

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERVENTION STUDY; MAJOR CLINICAL STUDY; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; UNSAFE SEX;

ADOLESCENT; ADULT; AIDS VACCINES; BEHAVIOR CONTROL; DISEASE TRANSMISSION, INFECTIOUS; DRUG USERS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; INTERVENTION STUDIES; MIDDLE AGED; RISK REDUCTION BEHAVIOR; UNSAFE SEX; YOUNG ADULT;

EID: 77649202734     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b7222e     Document Type: Article

References (38)

1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520-529
2. CDC. Subpopulation estimates from the HIV incidence surveillance system\ United States, 2006. MMWR Morb Mortal Wkly Rep 2008 57 985-989.
3. Gollub EL. A neglected population: drug-using women and women's methods of HIV/STI prevention. AIDS Educ Prev. 2008;20:107-120.
4. Ross MW, Hwang LY, Zack C, et al. Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine. Int J STD AIDS. 2002;13:769-774.
5. Sterk CE, Theall KP, Elifson KW. Who's getting the message? Intervention response rates among women who inject drugs and/or smoke crack cocaine. Prev Med. 2003;37:119-128.
6. Johnston MI, Fauci AS. An HIV vaccine\challenges and prospects. N Engl J Med. 2008;359:888-890.
7. Bartholow BN, Buchbinder S, Celum C, et al. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:90-101
8. UNAIDS. Ethical Considerations in HIV Preventive Vaccine Research. Geneva, Switzerland: UNAIDS 2000.
9. IOM (Institute of Medicine). Methodologic Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press 2008.
10. Darbes L, Crepaz N, Lyles C, et al. The efficacy of behavioral interventions in reducing HIV risk behaviors and incident sexually transmitted diseases in heterosexual African Americans. AIDS. 2008;22:1177-1194.
11. Neumann MS, Johnson WD, Semaan S, et al. Review and meta-analysis of HIV prevention intervention research for heterosexual adult populations in the United States. J Acquir Immune Defic Syndr. 2002;30(Suppl 1): S106-S117
12. US Department of Health and Human Services. Protection of Human Subjects. Code of Federal Regulations. Washington, DC: US Department of Health and Human Services 2003.
13. Mariner WK. Taking informed consent seriously in global HIV vaccine research. J Acquir Immune Defic Syndr. 2003;32:117-123.
14. Lindegger G, Richter LM. HIV vaccine trials: critical issues in informed consent. S Afr J Sci. 2000;96:313-317. (Pubitemid 30673085)
15. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793.
16. Koblin BA, Holte S, Lenderking B, et al. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. J Acquir Immune Defic Syndr. 2000;24: 451-457.
17. Coletti AS, Heagerty P, Sheon AR, et al. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2003;32:161-169.
18. Murphy DA, Hoffman D, Seage GR III, et al. Improving comprehension for HIV vaccine trial information among adolescents at risk of HIV. AIDS Care. 2007;19:42-51.
19. Joseph P, Schackman BR, Horwitz R, et al. The use of an educational video during informed consent in an HIV clinical trial in Haiti. J Acquir Immune Defic Syndr. 2006;42:588-591.
20. Murphy DA, O'Keefe ZH, Kaufman AH. Improving comprehension and recall of information for an HIV vaccine trial among women at risk for HIV: reading level simplification and inclusion of pictures to illustrate key concepts. AIDS Educ Prev. 1999;11:389-399.
21. Lindegger G, Slack C, Vardas E. HIV vaccine trials in South Africa\some ethical considerations. S Afr Med J. 2000;90:769-772. (Pubitemid 30734148)
22. Koblin BA, Xu G, Lucy D, et al. Hepatitis B infection and vaccination among high-risk noninjection drug-using women: baseline data from the UNITY study. Sex Transm Dis. 2007;34:917-922.
23. Latka M, Bonner S, Koblin B, et al. How well do high-risk women who are candidates for HIV vaccine efficacy trials understand HIV vaccine trial procedures and risk? A report from the UNITY Trial. Abstract presented at: American Public Health Association Meeting; December 10-14, 2005; Philadelphia, PA.
24. Bandura A. Social Foundations of Thought and Action: A Social Cognitive Theory. Englewood Cliffs, NJ: Prentice-Hall; 1986.
25. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280:1161-1167
26. Update on adult immunization. Recommendations of the Immunization Practices AdvisoryCommittee(ACIP).MMWR Recomm Rep. 1991;40:1-94.
27. Susser E, Desvarieux M, Wittkowski KM. Reporting sexual risk behavior for HIV: a practical risk index and a method for improving risk indices. Am J Public Health. 1998;88:671-674.
28. Colfax G, Vittinghoff E, Husnik MJ, et al. Substance use and sexual risk: a participant-and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol. 2004;159:1002-1012.
29. Fitzgerald DW, Marotte C, Verdier RI, et al. Comprehension during informed consent in a less-developed country. Lancet. 2002;360:1301-1302.
30. Sastry J, Pisal H, Sutar S, et al. Optimizing the HIV/AIDS informed consent process in India. BMC Med. 2004;2:28.
31. Flory J, Emanuel E. Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA. 2004;292:1593-1601.
32. Agre P, Campbell FA, Goldman BD, et al. Improving informed consent: the medium is not the message. IRB. 2003;25(Suppl):S11-S19
33. HIV Vaccine Trials Network. HVTN Manual of Operations, II. HVTN Policies and Procedures, Informed Consent. Available at: www.hvtn.org. Accessed January 9, 2009.
34. Kalichman SC, Adair V, Somlai AM, et al. The perceived social context of AIDS: study of inner-city sexually transmitted disease clinic patients. AIDS Educ Prev. 1995;7:298-307.
35. Adimora AA, Schoenbach VJ, Bonas DM, et al. Concurrent sexual partnerships among women in the United States. Epidemiology. 2002;13: 320-327.
36. Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis. 2005; 191(Suppl 1):S115-S122.
37. Senn TE, Carey MP, Vanable PA, et al. Sexual partner concurrency among STI clinic patients with a steady partner: correlates and associations with condom use. Sex Transm Infect. 2009. [Epub ahead of print].
38. Lindegger G, Milford C, Slack C, et al. Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa. J Acquir Immune Defic Syndr. 2006;43:560-566.